As equity investors caught up in the cannabis craze push pot stocks to record highs, options traders are paying the most ever to hedge against a comedown.

Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology - synthetic glucose binding molecules - for therapeutic and diagnostic applications.

Peptide drug FFW shows promise in reducing tumour growth and slowing down spread of cancer cells

Apple Inc. unveiled the most-significant upgrades to the Apple Watch since it first went on sale in 2015, turning the product into more of a health monitoring device.